Meridia Pediatric Adverse Events Will Get Continued Monitoring
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA notes that only one pediatric adverse case report was recorded and additional surveillance is necessary for a more meaningful analysis.
You may also be interested in...
Sparlon Shows 31 Cases Of Suicidality, Aggression or Psychosis In ADHD Database
Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.
Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says
Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.